Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 954 | Ordered by Deal: Collaboration or Financing (ascending)
1 2 3 4 5 6 7 8 9 10  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
10x Genomics–Fidelity: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Fidelity 2019-01-07
10x Genomics–Meritech Capital: investment, 201901 financing round Series D extension totalling $35m incl existing + lead investor Meritech Capital 2019-01-07
10x Genomics–SEVERAL: investment, 201901 financing round Series D extension $35m led by Meritech Capital + incl Fidelity + Wells Fargo 2019-01-07
10x Genomics–Wells Fargo: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Wells Fargo 2019-01-07
4DCellFate project–CLC bio: stem cell research, 201202– 5y CLC bio AS is partner in FP7 project 2012-02-13
4DCellFate project–EU (govt): grant, 201202– 5y FP7 grant €12m 2012-02-13
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
Ablynx–Algeta: cancer drugs, 201211– collab research to evaluate thorium-227 alpha-pharmaceutical with Nanobodies to treat cancer 2012-11-21
Ablynx–Novo Group: investment, 201712– acquisition unsolicited cash offer €2.6b up to €30.5/share ANNOUNCED + REJECTED 2017-12-22
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Abunda Nutrition–Evolva: food ingredients, 201010– collab expansion + extension €na 2y research production methods for high-value food ingredients 2010-10-25
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–SEVERAL: investment, 201309 financing round Series B £15m led by new invesors Fidelity Biosciences + Novo A/S 2013-09-03
Acacia Pharma–SEVERAL: investment, 201802–201803 initial global offering €40m private placement 11.1m shares at €3.6 + listing on Euronext Brussels 2018-02-05
ACE Biosciences–Zymenex: investment, 200911 acquisition 2009-11-09
Acesion Pharma–SEVERAL: investment, 201611 financing round Series A €9.1m from Wellcome Trust + Novo Seeds 2016-11-01
Acino–Nordic Capital: investment, 201310– public tender offer CHF398m with CHF115/share by Avista Capital Partners + Nordic Capital 2013-10-02
aCROnordic–Manipal: investment, 201103–2012 acquisition of aCROnordic A/S by Ecron Acunova GmbH 2011-03-28
Actavis–Bioton: insulin products, 201201– collab + jv €55.5m with €22.25m upfront developm + production by Bioton + sales in Europe + US by Actavis 2012-01-30
Actavis–Watson: investment, 201204–201210 acquisition €4.15b in cash + milestone-based issue of up to 5.5m common shares (approx €250m) 2012-04-25
Actelion–Qlucore: bioinformatics, 201507– license 3y to Omics Explorer s/w after using it since 2011 2015-07-01
Action Pharma–Abbott: AP214, 201205 acquisition $110m of AP214 by Abbott 2012-05-01
Active Biotech–Evotec: drug discovery services, 201003– service €na identification of small molecule leads by HT screening for specific target 2010-03-11
Active Biotech–Evotec: drug discovery services, 201106– service €na medicinal chemistry services after successful HTS 2011-06-06
Active Biotech–Evotec: drug discovery services, 201204– service €na expansion medicinal chemistry services drug optimisation 2012-04-26
Active Biotech–Investor AB: investment, 201303 capital increase SEK270m 6m new shares SEK45/share sold to Investor AB 2013-03-06
Active Biotech–SEVERAL: investment, 201001 private placement SEK375m 2.5m new shares SEK150/share 2011-01-26
Active Biotech–SEVERAL: investment, 201412 rights issue SEK225m with 15m new shares issued 2014-12-29
ADITEC project–EU (govt): grant, 201110–201609 funding €29.98m from EU out of total project cost of €41m 2011-10-01
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock 2015-07-14
Aerocrine–Circassia: investment, 201506 acquisition of Aerocrine AB by Circassia 2015-06-18
Aerocrine–Odlander Fredrikson: investment, –201506 existent investment listed on HealthCap web site 2015-06-18
Affimed–Novo Group: investment, 201210 financing round Series D totalling €15.5m incl investor Novo Nordisk A/S 2012-10-08
Agilent–Applied Spectral Imaging: FISH technology, 201604– collab co-marketing of GenASIs imaging platform w Agilent FISH products + solutions 2016-04-07
Agilent–Cell Signaling Technology: diagnostic antibodies, 201501– supply €na strategic partnership to supply ABs for Dako companion Dx products 2015-01-12
Agilent–System Dynamics: connectivity software, 201212 acquisition of IP + development team €na by Dako 2012-12-21
AH Diagnostics–Aushon BioSystems: ELISA technology, 201210– excl distribution of Cira platform products for multiplex ELISAs in Scandinavia 2012-10-30
Ahma–Eurofins: investment, 201704 acquisition of 2nd largest Finnish environmental testing lab Ahma Group by Eurofins 2017-04-04
Airsonett–Sweden (govt): investment, 201201 existent investment of Industrifonden 2012-01-05
Ajinomoto–Albireo: elobixibat, 201204– license excl for developm + commercialisation in Japan + Korea + Thailand + Indonesia + Vietnam + Taiwan 2012-04-03
Alba Therapeutics–Odlander Fredrikson: investment, 201507 existent investment listed on HealthCap web site 2015-07-23
Alder Biopharmaceuticals–Lundbeck: investment, 201909–201910 acquisition tender offer in cash + CVRs up to $1.95b net of cash 2019-09-16
Algeta–Bayer: investment, 201311– acquisition proposal by Bayer NOK362/share valuing Algeta equity at €2.1b 2013-11-26
Algeta–Huntsworth: public relations, 201106 service existent by Citigate Dewe Rogerson 2011-05-31
Alizé Pharma–SEVERAL: investment, 201907 financing round Series A €67m of Alizé Pharma 3 led by LSP 2019-07-31
Alligator Bioscience–Aptevo Therapeutics: antibody cancer drug, 201707– collab developm bispecific antibody ALG.APV-527 for I-O 2017-07-21
Alligator Bioscience–Investor AB: investment, 201508 existent Sunstone + Investor AB via DUBA AB are largest shareholders 2015-08-12
Alligator Bioscience–JnJ: investment, 201508 capital increase JnJ Innovation JJDC Inc acquires new shares in connection w collab for ADC-1013 2015-08-12
Alligator Bioscience–SEVERAL: investment, 201103 financing round SEK43m directed new share issue lead investor Sunstone Capital SEK12/share 2011-03-31
Alligator Bioscience–Sunstone Capital: investment, 201508 existent Sunstone + Investor AB are largest shareholders 2015-08-12
Alligator Bioscience–Sweden (govt): investment, 201201 existent investment of Industrifonden 2012-01-05
Almirall–InDex Pharmaceuticals: Kappaproct, 201404– license European marketing rights total deal value incl milestones €100m 2014-04-01
Altair–Pharmacia AB: laboratory equipment, 1983– distribution Altair becomes distributor in Japan for Pharmacia (SE) 1983-01-01
Alvogen–Insilico Biotechnology: bioinformatics, 201511– collab Alvotech using Insilico simulation s/w to develop biosimilars using mammalian cells 2015-11-27
Alzinova–SEVERAL: investment, 201508 financing round SEK5m ($580k) 2015-08-03
Alzinova–SEVERAL: investment, 201510 IPO SEK16.7m (€1.78m) net SEK15.4m + 2 warrants for each 3 shares at AktieTorget 2015-10-27
Alzinova–Sweden (govt): grant, 201502– »Innovationsprojekt i företag« grant from Vinnova for Alzheimer vaccine program ALZ-101 2015-06-26
Amarna Therapeutics–Flerie Invest: investment, 201910 financing round totalling €10m incl lead investor Flerie Invest AB + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–Netherlands (govt): credit, 201910 financing round totalling €10m incl substantial innovation credit from 2019-10-16
Amarna Therapeutics–PERSON: investment, 201910 financing round totalling €10m incl existing + co-investor Pim Berger + incl RVO innovation credit 2019-10-16
Amarna Therapeutics–SEVERAL: investment, 201910 financing round €10m led by Flerie Invest AB + incl innovation credit from 2019-10-16
Amgen–Dako: companion diagnostic, 201201– collab developm pharmDx companion test for Amgen cancer drug candidate 2012-01-10
Amgen–Dako: companion diagnostic, 201202– collab developm PhamrDx companion test for 2nd Amgen cancer drug candidate 2012-01-10
Amplidiag–Mobidiag: investment, 201304 merger in shares with Genewave SAS + Amplidiag Oy becoming subsidiaries of Mobidiag Oy 2013-04-12
Anergis–SEVERAL: investment, 201604 financing round extension CHF5m to conduct phase 2b study with AllerT from existing investors 2016-04-04
Ani Labsystems–Trivitron: investment, 201211 acquisition €15.8m of 100% of Ani Labsystems group by Trivitron Healthcare 2012-11-23
Antag Therapeutics–Novo Group: investment, 201706 seed financing €2.7m by Novo Seeds 2017-06-26
AntibioTx–EU (govt): credit, 201710– EIB loan €20m to AntibioTx A/S for antibotics development 2017-10-26
APIM Therapeutics–SEVERAL: investment, 201210 financing round led by Norsk Innovasjonskapital III AS 2012-10-17
APIM Therapeutics–Telenor: investment, 201210 financing round led by Norsk Innovasjonskapital III AS resulting 26.3% share 2012-10-17
Aprea–MC Services: public relations, 201602 service existent for Aprea AB 2016-03-09
Aprea–SEVERAL: investment, 201603 financing round Series B €46m co-led by Versant Ventures + 5AM Ventures incl HealthCap et al 2016-03-09
Aprea–SEVERAL: investment, 201812 financing round Series C €50m led by new investor Redmile Group 2018-12-02
Aprea–Sweden (govt): investment, 201201 existent investment of Industrifonden 2012-01-05
Apta Biosciences–EU (govt): grant, 201511– Horizon 2020 grant €940k as part of MARA project to develop new antiinfectives 2015-11-01
Ascendis Pharma–SEVERAL: investment, 201412 financing round Series D $60m co-led by Sofinnova Ventures + orbiMed + Vivo Capital 2014-12-01
Ascendis Pharma–SEVERAL: investment, 201610 public offering $120m with 6.3m ADSs at $19/ADS 2016-10-18
Ascendis Pharma–SEVERAL: investment, 201709 public offering $134m+20m with 3.8m+570k ADSs at $35.5/ADS 2017-09-26
Ascendis Pharma–SEVERAL: investment, 201802 public offering $225m net $210m with 3.95m ADSs at $57/ADS 2018-02-20
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Ascendis Pharma–Spark BioComm: public relations, 201712 service existent by Spark BioComm 2017-12-21
Ascendis Pharma–Westwicke Partners: public relations, 201712 service existent IR by Westwicke Partners 2017-12-21
Astellas–Leo Pharma: investment, 201511 acquisition €675m asset purchase of global dermatology portfolio of Astellas by Leo Pharma 2015-11-11
AstraZeneca–Alchemia: drug discovery services, 201304– collab using VAST technology to discover small molecules against multiple AZ targets 2013-04-23
AstraZeneca–Dentsply: investment, 201106 acquisition of Astra Tech business for $1.8b in cash by Dentsply 2011-06-22
AstraZeneca–Karolinska Institutet: drug development, 201303– collab establishment of joint Integrated Translational Research Centre in Stockholm 2013-03-21
AstraZeneca–KTH (SE): proteomics, 201512– collab research w new Wallenberg Centre for Protein Research based on secretome analysis 2015-12-11
AstraZeneca–Lipigon Pharmaceuticals: cardiovascular drugs, 201603– collab up to $110m milestones drug discovery LPL-stabilizing small-molecule drugs 2016-03-14
AstraZeneca–Pelago Bioscience: drug discovery technology, 201511–201710 license + collab developm CETSA to analyse drug-target interactions 2015-11-27
AstraZeneca–Univ Helsinki: genomics, 201604– collab FIMM is one of three initial partners in AZ’s new integrated strategic genomics initiative 2016-04-22
Asuragen–Exiqon: real-time PCR technology, 201306– supply Service Center Agreem for use of miRCURY LNA Universal RT microRNA PCR products by Asuragen 2013-06-10
Athera Biotechnologies–Karolinska Development: investment, 201512 DIVESTMENT of entire shareholding in Athera for an earn-out 2015-12-03
Aurealis Pharma–SEVERAL: investment, 201708 financing round Series A CHF5.6m from private investors + Finnvera + Tekes 2017-08-25
Avilex Pharma–Novo Group: investment, 201304 seed financing from Novo Seeds 2013-04-15
AvroBio–Univ Lund: gene therapy, 201703– license + collab agreement €na for Gaucher disease gene therapy 2017-03-22
Bavarian Nordic–EU (govt): credit, 201808– EIB loan €30m to support construction + validation of vaccine manufacturing facility 2018-08-09
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Bavarian Nordic–JnJ: investment, 201410– acquisition of up to 1.67m new shares for DKK251m ($43m) by J&JDC representing up to 6.4% shareholding 2014-10-22
1 2 3 4 5 6 7 8 9 10  next pagenext page


Picture Kentro Design Corporate and Web Design Berlin 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px

» top